


Accepted Manuscript

Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment



Seung Woo Chung, Gui Chul Kim, Seho Kweon, Hanul Lee, Jeong Uk Choi, Foyez Mahmud, Hyo Won Chang, Ji Won Kim, Woo-Chan Son, Sang Yoon Kim, Youngro Byun

PII: S0142-9612(18)30561-1
DOI: 10.1016/j.biomaterials.2018.08.007
Reference: JBMT 18813
To appear in: *Biomaterials*
Received Date: 26 January 2018
Accepted Date: 03 August 2018

Please cite this article as: Seung Woo Chung, Gui Chul Kim, Seho Kweon, Hanul Lee, Jeong Uk Choi, Foyez Mahmud, Hyo Won Chang, Ji Won Kim, Woo-Chan Son, Sang Yoon Kim, Youngro Byun, Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment, *Biomaterials* (2018), doi: 10.1016/j.biomaterials.2018.08.007

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment

Seung Woo Chung^{1,2,3}, Gui Chul Kim⁴, Seho Kweon⁵, Hanul Lee¹, Jeong Uk Choi¹, Foyez Mahmud⁵, Hyo Won Chang⁴, Ji Won Kim⁴, Woo-Chan Son^{6,7}, Sang Yoon Kim^{4*}, and Youngro Byun^{1,5*}

¹Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, South Korea, ²Center for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, United States, ³Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, United States, ⁴Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea, ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergent Science and Technology, Seoul National University, Seoul 08826, South Korea, ⁶Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea, ⁷Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Short title: Metronomic oral doxorubicin and MK-8776 combination therapy

***Correspondence to:** Youngro Byun, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergent Science and Technology, Seoul National University, Seoul 08826, South Korea, Tel.: +82-2-880-7866, E-mail: yrbyun@snu.ac.kr, and Sang Yoon Kim, Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea, Tel.: +82-2-3010-3715, E-mail: sykim2@amc.seoul.kr

First Authors: Seung Woo Chung and Gui Chul Kim have equally contributed to the study as the first authors.

Download English Version:

<https://daneshyari.com/en/article/6484284>

Download Persian Version:

<https://daneshyari.com/article/6484284>

[Daneshyari.com](https://daneshyari.com)